Skip to main content

Truist Financial Reaffirms Their Hold Rating on SAGE Therapeutics (SAGE)

Tipranks - Tipranks - Wed Jun 18, 2025

Truist Financial analyst Joon Lee maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $9.00. The company’s shares closed yesterday at $9.07.

Confident Investing Starts Here:

According to TipRanks, Lee is a 5-star analyst with an average return of 19.8% and a 47.81% success rate. Lee covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Jazz Pharmaceuticals, and Argenx Se.

The word on The Street in general, suggests a Hold analyst consensus rating for SAGE Therapeutics with a $8.88 average price target, which is a -2.09% downside from current levels. In a report released today, Piper Sandler also downgraded the stock to a Hold with a $8.50 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $13.47 and a one-year low of $4.62. Currently, SAGE Therapeutics has an average volume of 1.39M.

Read More on SAGE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).